1246834-64-9 Usage
Uses
Used in Organic Synthesis:
Pyrimidin-2-ylmethanamine acetate is used as a building block for the synthesis of various organic compounds due to its versatile chemical structure and reactivity.
Used in Medicinal Chemistry:
Pyrimidin-2-ylmethanamine acetate is used as a precursor in the development of pharmaceutical compounds for its potential to be incorporated into drug molecules, contributing to their therapeutic properties.
Used in Pharmaceutical Industry:
Pyrimidin-2-ylmethanamine acetate is used as an intermediate in the synthesis of active pharmaceutical ingredients (APIs) for its ability to be modified and functionalized to create new drug candidates with potential therapeutic applications.
Used in Research and Development:
Pyrimidin-2-ylmethanamine acetate is used as a research tool in the study of chemical reactions and mechanisms, as well as in the exploration of new chemical entities with potential applications in various fields, including materials science and biology.
Check Digit Verification of cas no
The CAS Registry Mumber 1246834-64-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,6,8,3 and 4 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1246834-64:
(9*1)+(8*2)+(7*4)+(6*6)+(5*8)+(4*3)+(3*4)+(2*6)+(1*4)=169
169 % 10 = 9
So 1246834-64-9 is a valid CAS Registry Number.
1246834-64-9Relevant articles and documents
NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER
-
, (2012/04/17)
The present invention is to provide a therapeutic agent for attention deficit/hyperactivity disorder having a novel mechanism of action which is different from conventional psychostimulants. The present invention is useful for providing an excellent pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder, comprising a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, and is particularly useful for providing a pharmaceutical composition for prevention and/or treatment of inattention, impulsivity, and hyperactivity in attention deficit/hyperactivity disorder.
NOVEL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SCHIZOPHRENIA
-
Page/Page column 5, (2010/10/19)
The present invention is useful for providing an excellent pharmaceutical composition for prevention and/or treatment of schizophrenia, containing a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, and is particularly useful for providing a pharmaceutical composition for prevention and/or treatment of the positive symptoms, negative symptoms, cognitive impairments and the like of schizophrenia.
